Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Bone Biologics Corp(BBLG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBLG
09/25/2026: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Bone Biologics Corp is a pre-revenue, clinical-stage biotechnology company developing the NELL-1 protein platform for spinal fusion procedures. Its primary strength lies in its specialized focus and proprietary technology, which aims to provide a superior alternative to existing bone graft materials. The company's growth hinges on successful clinical trial outcomes and eventual FDA approval, representing a classic high-risk, high-reward biotech investment story. Key risks include significant regulatory hurdles, heavy reliance on capital raises, and intense competition from established medical device leaders. It is best suited for growth-oriented investors with high risk tolerance who are closely monitoring updates from the company's ongoing clinical development programs.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to biotech innovation but lacks established product sales. |
| Momentum investor | Mixed fit | Momentum may occur around clinical trial updates, but requires a positive technical upturn signal. |
| Value investor | Weak fit | The company is in a pre-revenue stage, making traditional value metrics like P/E ratios inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for research and development. |
| Low-risk investor | Weak fit | The high volatility and regulatory risks of biotech development are generally unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical news, which can lead to significant swings. |
| Valuation risk | High | Valuation is speculative and heavily dependent on the uncertain probability of future regulatory success. |
| Competition risk (incumbent medical device firms) | High | It must compete against massive firms with entrenched relationships and resources. |
| Business quality | Medium | While the technology is novel, the company is still proving its commercial viability. |
| Dividend income | Low / none | Investors should expect zero income from this equity. |
| Execution risk | High | Successfully navigating FDA pathways and clinical trials is a complex and risky undertaking. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -63.36% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37M USD | Price to earnings Ratio - | 1Y Target Price 12.2 |
Price to earnings Ratio - | 1Y Target Price 12.2 | ||
Volume (30-day avg) 239.9K shares | Beta 0.5 | 52 Weeks Range 0.43 - 2.89 | Updated Date 09/26/2026 |
52 Weeks Range 0.43 - 2.89 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Osteobiologics Research | Future sales potential from NELL-1 technology applications. | The company is currently betting on the future regulatory success of its bone-growth protein. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2.64M | Price to Sales(TTM) - |
Enterprise Value -2.64M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 2.76M | Shares Floating 2.76M |
Shares Outstanding 2.76M | Shares Floating 2.76M | ||
Percent Insiders 0.02 | Percent Institutions 5.01 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Bone Biologics Corp
Exchange NASDAQ | Headquarters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.